Ropes & Gray advised Madrigal Pharmaceuticals in an exclusive global license agreement with CSPC Pharmaceutical Group Limited for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist. The transaction was announced on July 30.
Under the agreement Madrigal will pay CSPC $120 million upfront and up to $2 billion in potential milestone payments plus royalties on net sales.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associate Ryan Kramer and included tax partner David Saltzman and litigation & enforcement partner Lisa Kaltenbrunner.